BRAF Mutation Management in Metastatic Colorectal Cancer

Metastatic colorectal cancer (mCRC) harbouring BRAF mutations, most frequently the V600E variant, accounts for approximately 8–12% of cases and is associated with aggressive clinical behaviour and poor prognosis. BRAF encodes a serine/threonine kinase within the MAPK signalling cascade, and its constitutive activation drives tumour growth, survival and therapeutic resistance. Historically, management relied on cytotoxic chemotherapy regimens such as FOLFOX or FOLFIRI, often combined with anti-angiogenic agents. The limited efficacy of single-agent BRAF inhibitors led to the development of combination approaches targeting both upstream receptor tyrosine kinases (notably EGFR) and downstream effectors (MEK), which improved response rates but remained hampered by primary and acquired resistance. Recent advances have integrated immunotherapy, molecular stratification by RNF43 and microsatellite status, and exploration of the tumour microenvironment to refine treatment sequencing. Despite progress, median survival remains under 20 months, underscoring an ongoing need for predictive biomarkers and novel combination strategies to overcome adaptive resistance and extend patient benefit globally.

Research from Nature Portfolio

Recent clinical studies of combined PD-1, BRAF and MEK inhibition in BRAF V600E mCRC have demonstrated improved overall response rates and more durable disease control compared with BRAF/MEK blockade alone, revealing a cooperative mechanism between MAPK pathway suppression and tumour-intrinsic immune activation. Mechanistic research has uncovered compensatory activation of SRC kinases following BRAF±EGFR inhibition, driven by an autocrine prostaglandin E₂/COX2 loop; co-targeting COX2 alongside BRAF and EGFR blockers achieves more durable tumour suppression in preclinical models. Complementary genomic analyses indicate that inactivating mutations in RNF43, a negative regulator of Wnt signalling, predict enhanced responsiveness to anti-BRAF/EGFR therapy in microsatellite-stable tumours, highlighting MAPK–Wnt pathway cross-talk as a determinant of clinical outcome.

BRAF Mutation Management in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in braf mutation management in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

BRAF V600E mutation: A point mutation in the BRAF gene resulting in constitutive kinase activity within the MAPK pathway.

MAPK pathway: A signalling cascade (RAS–RAF–MEK–ERK) that regulates cell proliferation and survival, often dysregulated in cancer.

EGFR: Epidermal growth factor receptor, a cell-surface tyrosine kinase that activates downstream proliferative pathways.

PD-1: Programmed cell death protein 1, an immune checkpoint receptor on T cells targeted by immunotherapy to enhance anti-tumour immunity.

RNF43: An E3 ubiquitin ligase that negatively regulates Wnt signalling; loss-of-function mutations can modulate response to targeted therapy.

COX2: Cyclooxygenase-2, an inducible enzyme involved in prostaglandin synthesis and inflammation, implicated in therapy resistance.

Wnt/β-catenin pathway: A developmental signalling pathway whose dysregulation promotes tumour progression and therapeutic resistance.

Chaperone-mediated autophagy (CMA): A selective lysosomal degradation process mediated by heat shock proteins that regulates protein quality and signalling.

References

1. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine (2023).
2. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. Nature Cancer (2023).
3. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nature Medicine (2022).
4. European expert panel consensus on the clinical management of BRAFV600E -mutant metastatic colorectal cancer. Cancer Treatment Reviews (2023).
5. HSPA8 Activates Wnt/β‐Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA‐Mediated CAV1 Degradation. Advanced Science (2023).